Eric Bjerkholt Sells 20,000 Shares of Cerus Co. (NASDAQ:CERS) Stock

Cerus Co. (NASDAQ:CERS) Director Eric Bjerkholt sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $1.78, for a total transaction of $35,600.00. Following the sale, the director now owns 162,133 shares of the company’s stock, valued at $288,596.74. The trade was a 10.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Cerus Stock Performance

Shares of CERS opened at $1.69 on Wednesday. Cerus Co. has a one year low of $1.38 and a one year high of $2.59. The company has a 50-day moving average of $1.75 and a two-hundred day moving average of $1.91. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The stock has a market cap of $313.86 million, a price-to-earnings ratio of -15.36 and a beta of 1.24.

Wall Street Analysts Forecast Growth

Separately, Stifel Nicolaus cut their price objective on Cerus from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Thursday, October 17th.

Hedge Funds Weigh In On Cerus

Several institutional investors and hedge funds have recently added to or reduced their stakes in CERS. Secure Asset Management LLC purchased a new stake in shares of Cerus in the second quarter valued at $27,000. Creative Planning raised its position in Cerus by 51.3% during the third quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 8,411 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in Cerus in the 2nd quarter worth about $45,000. Intech Investment Management LLC acquired a new stake in Cerus during the 3rd quarter worth about $71,000. Finally, Algert Global LLC purchased a new position in Cerus during the 2nd quarter valued at about $97,000. 78.37% of the stock is currently owned by hedge funds and other institutional investors.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.